The Center for Biosimilars® recaps the top stories for the week of January 20, 2020.
Hi, I’m Gianna Melillo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 20, 2020
Number 5: Celltrion announces that it plans to launch 10 biosimilars over the next decade and will also open a large biologics manufacturing plant in China.
Number 4: A healthcare executive writes that providers should be able to help their patients reduce their out-of-pockets costs while providing the highest-quality care available through oncology biosimilars.
Number 3: Alvotech and JAMP Pharma announce a partnership to commercialize 5 biosimilars in the Canadian market.
Number 2: Gilead Science’s new chairman and chief executive officer outlines a growth plan at the J.P. Morgan Healthcare Conference.
Number 1: Teva Pharmaceuticals touts the launch of its biosimilar rituximab, Truxima, as evidence that it knows how to navigate the US pharmaceutical system.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.